microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma

References

• Boyle P, Levin B. World cancer report 2008. WHO Press, Avenue,Geneva, Switzerland 2009:pp350
   Google Scholar
• Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 Suppl 4:5-13; PMID:21115576; http://dx.doi.org/10.1634/theoncologist.2010-S4-05
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res 2012; 42:368-75; PMID:22151896; http://dx.doi.org/10.1111/j.1872-034X.2011.00929.x
   PubMed Web of Science ®Google Scholar
• Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012; 6:207-19; PMID:22904613
   PubMedGoogle Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27; PMID:21992124; http://dx.doi.org/10.1056/NEJMra1001683
   PubMed Web of Science ®Google Scholar
• Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012; 12:613-26; PMID:22898542; http://dx.doi.org/10.1038/nrc3318
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Taylor MA, Schiemann WP. Therapeutic Opportunities for Targeting microRNAs in Cancer. Mol Cell Ther 2014; 2:1-13; PMID:25717380; http://dx.doi.org/10.1186/2052-8426-2-30
   PubMedGoogle Scholar
• Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer 2015; 14:5; PMID:25608619; http://dx.doi.org/10.1186/1476-4598-14-5
   PubMed Web of Science ®Google Scholar
• Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z, Guo C, Liu Y, Chen Z, Wang X, Chen D, Wei H, Wang S. MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett 2015; 356:809-18; PMID:25449782; http://dx.doi.org/10.1016/j.canlet.2014.10.041
   PubMed Web of Science ®Google Scholar
• Guo XB, Jing CQ, Li LP, Zhang L, Shi YL, Wang JS, Liu JL, Li CS. Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. World J Gastroenterol 2011; 17:1895-902; PMID:21528065
   PubMed Web of Science ®Google Scholar
• Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y, Cuatrecasas M, Arnold M, Meltzer SJ, Syngal S, et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res 2011; 17:6239-49; PMID:21844009; http://dx.doi.org/10.1158/1078-0432.CCR-11-1424
   PubMed Web of Science ®Google Scholar
• Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wojdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 2012; 25:1609-22; PMID:22878649; http://dx.doi.org/10.1038/modpathol.2012.122
   PubMed Web of Science ®Google Scholar
• Han Z, Yang Q, Liu B, Wu J, Li Y, Yang C, Jiang Y. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis 2012; 33:131-9; PMID:22016468; http://dx.doi.org/10.1093/carcin/bgr226
   PubMed Web of Science ®Google Scholar
• Zhang R, Luo H, Wang S, Chen Z, Hua L, Wang HW, Chen W, Yuan Y, Zhou X, Li D, et al. miR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells. J Neurooncol 2015; 121:63-72; PMID:25258251; http://dx.doi.org/10.1007/s11060-014-1607-y
   PubMed Web of Science ®Google Scholar
• Chen G, Lu L, Liu C, Shan L, Yuan D. MicroRNA-377 Suppresses Cell Proliferation and Invasion by Inhibiting TIAM1 Expression in Hepatocellular Carcinoma. PLoS One 2015; 10:e0117714; PMID:25739101; http://dx.doi.org/10.1371/journal.pone.0117714
   PubMedGoogle Scholar
• Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011; 17:710-20; PMID:21196414; http://dx.doi.org/10.1158/1078-0432.CCR-10-0331
   PubMed Web of Science ®Google Scholar
• Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012; 208:541-8; PMID:22824148; http://dx.doi.org/10.1016/j.prp.2012.06.001
   PubMed Web of Science ®Google Scholar
• Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res 2008; 14:7043-9; PMID:18981001; http://dx.doi.org/10.1158/1078-0432.CCR-08-0381
   PubMed Web of Science ®Google Scholar
• Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, Tian K, Li X, Zhu S, Niu Y, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 2013; 12:2569-80; PMID:24013097; http://dx.doi.org/10.1158/1535-7163.MCT-13-0296
   PubMed Web of Science ®Google Scholar
• Gaken J, Mohamedali AM, Jiang J, Malik F, Stangl D, Smith AE, Chronis C, Kulasekararaj AG, Thomas NS, Farzaneh F, et al. A functional assay for microRNA target identification and validation. Nucleic Acids Res 2012; 40:e75; PMID:22323518; http://dx.doi.org/10.1093/nar/gks145
   PubMedGoogle Scholar
• Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006; 103:3775-80; PMID:16537454; http://dx.doi.org/10.1073/pnas.0600040103
   PubMed Web of Science ®Google Scholar
• Das M, Garlick DS, Greiner DL, Davis RJ. The role of JNK in the development of hepatocellular carcinoma. Genes Dev 2011; 25:634-45; PMID:21406557; http://dx.doi.org/10.1101/gad.1989311
   PubMed Web of Science ®Google Scholar
• Lee EK, Kim HJ, Lee KJ, Lee HJ, Lee JS, Kim DG, Hong SW, Yoon Y, Kim JS. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol 2011; 38:325-33; PMID:21132267
   PubMed Web of Science ®Google Scholar
• Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, et al. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int 2010; 30:1522-8; PMID:21040406; http://dx.doi.org/10.1111/j.1478-3231.2010.02336.x
   PubMed Web of Science ®Google Scholar
• Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, Wang J, Lu Z, Song X, Pei T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappaB drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology 2014; 60:1659-73; PMID:25042864; http://dx.doi.org/10.1002/hep.27312
   PubMed Web of Science ®Google Scholar
• Wu LF, Li GP, Su JD, Pu ZJ, Feng JL, Ye YQ, Wei BL. Involvement of NF-kappaB activation in the apoptosis induced by extracellular adenosine in human hepatocellular carcinoma HepG2 cells. Biochem Cell Biol 2010; 88:705-14; PMID:20651843; http://dx.doi.org/10.1139/O10-008
   PubMed Web of Science ®Google Scholar
• Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. International Union against Cancer: Wiley-Blackwell, 2010
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Wang Y, Shek FH, Wong KF, Liu LX, Zhang XQ, Yuan Y, Khin E, Hu MY, Wang JH, Poon RT, et al. Anti-cadherin-17 antibody modulates β-catenin signaling and tumorigenicity of hepatocellular carcinoma. PLoS One 2013; 8:e72386; PMID:24039755; http://dx.doi.org/10.1371/journal.pone.0072386
   PubMedGoogle Scholar